To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Tandem Diabetes Care Conference Summary Company Overview - **Company**: Tandem Diabetes Care (NasdaqGM:TNDM) - **Event**: 2026 Conference - **Date**: February 26, 2026 Key Points Industry and Market Dynamics - Tandem is undergoing a significant commercial transformation, expanding its sales force and introducing new tools and systems to enhance market approach [7][9] - The company is focusing on direct sales in international markets, having launched operations in Switzerland, Austria, and the U.K. [18] - The transition to a direct sales model is expected to increase average selling prices (ASP) by at least 30% in various markets [19] Financial Performance - In Q4 2025, Tandem reported record sales and margins, achieving a gross margin of 58%, the highest in its history [125] - The company experienced a revenue growth of 10%-11% year-over-year in pump shipments, with expectations to maintain this growth [89][103] - The transition to a pay-as-you-go model is anticipated to temper revenue growth in the short term but is expected to yield significant benefits in 2027 and beyond [92][129] Product Launches and Innovations - The launch of FreeStyle Libre 3 with t:slim and Mobi with Android is expected to expand the addressable market significantly [11][35] - Mobi's tubeless feature is set to launch in the second half of 2026, which is anticipated to enhance user experience and adoption [40][41] - Tandem is integrating new technologies, including a dual glucose-ketone sensor, into its insulin delivery systems [58] Sales Strategy and Distribution - Tandem is shifting its sales strategy to include pharmacy channels, which is expected to provide a higher reimbursement stream compared to traditional durable medical equipment (DME) channels [75][78] - The company plans to have 20% of its pumps shipped through pharmacy channels in 2026, with a long-term goal of reaching 70% [100][102] - The ASP for supplies in pharmacy is projected to be four times higher than in DME, contributing to a more predictable revenue stream [78][79] Customer Retention and Market Position - Tandem has a strong customer retention rate, with 70% of customers purchasing a second pump within 18 months [112] - The company believes that the quality of its products and algorithms will keep customers loyal, even as they explore other options [112][131] Challenges and Future Outlook - Tandem anticipates a $70 million to $80 million headwind in 2026 due to the transition to the pay-as-you-go model [88][92] - The company is focused on shifting existing patients to the new model, which is expected to mitigate headwinds in subsequent years [92] - Future discussions are expected to revolve around the success of the pharmacy model and customer feedback on new product features [138][140] Conclusion - Tandem Diabetes Care is positioned for growth through strategic product launches, a shift to pharmacy channels, and a focus on customer retention. The company is optimistic about its long-term prospects despite short-term challenges related to its new business model.

Core Viewpoint - Tandem Diabetes Care, Inc. has announced the pricing of $265.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032 in a private placement aimed at qualified institutional buyers under Rule 144A of the Securities Act [1] Group 1 - The offering of the convertible senior notes was upsized from a previously announced amount [1]

Tandem Diabetes Care, Inc. ( TNDM ) beat out expectations in Q4 '25. GAAP EPS came in at -$0.01, which was actually $0.05 above the consensus. Elsewhere, revenue for the quarter hit $290.4 million, up about 2.8% year-over-year and $13.16 million ahead of forecasts. There wereI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic rese ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78. The firm believes the bias across its dental names remains to the upside.UBS upgraded BlackRock (BLK) to Buy from Neutral with a $1,280 price target. The upgrade is supported by strong Q4 results, positive comme ...

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the fourth quarter of 2025, the Small Company Fund (Investor shares) fell 1.50%, behind the Russell 2000® Growth index's 1.22% gain. Real estate and telecommunications businesses led the benchmark's performance for the quarter. The Fund was down 11.46% in 2025, significantly lagging the Index’s 13.0 ...

Core Viewpoint - Tandem Diabetes Care is transitioning to a more predictable and lucrative business model, resulting in significant profitability gains and a notable increase in stock price [1][3]. Group 1: Financial Performance - Tandem's sales increased by 3% year-over-year, reaching $290 million in the fourth quarter, with worldwide insulin pump shipments totaling 38,000 units, including 27,000 in the U.S. [3] - The company's gross margin improved to 58%, up from 56% in the same quarter last year, contributing to an operating income of $8.3 million, compared to a loss of $0.6 million in the prior-year period [5]. - The market capitalization of Tandem is currently $1.3 billion, with a stock price increase of 32.67% to $24.57 [4]. Group 2: Business Model and Future Outlook - Tandem is adopting a pay-as-you-go pharmacy structure, which reduces upfront costs for customers and generates recurring revenue, aligning with the company's goal of achieving more predictable and profitable revenue streams [3][7]. - For 2026, Tandem anticipates full-year sales between $1.065 billion and $1.085 billion, with projected gross margins of 56% to 57% [7]. - The CEO highlighted 2025 as a pivotal year, marking over $1 billion in worldwide sales and record gross margins while modernizing commercial operations and reshaping the business model [6].

Core Viewpoint - Tandem Diabetes reported better-than-expected financial results, showing improvements in sales and profitability, while also providing guidance for future growth despite a slight miss on sales expectations for fiscal 2026 [2][3][4]. Financial Performance - The company reported a fourth quarter adjusted loss of one cent, compared to the consensus loss of eight cents [2]. - Sales increased by 3% year over year to $290.4 million, surpassing the consensus estimate of $277.03 million [2]. - Adjusted gross profit rose from 51% to 58%, and adjusted operating profit was $8.3 million, a significant improvement from a loss of $30.2 million a year ago [2]. Guidance - For fiscal 2026, Tandem Diabetes forecasts sales between $1.065 billion and $1.085 billion, slightly below the consensus of $1.103 billion [3]. - The company anticipates an adjusted EBITDA margin of approximately 5% to 6% [3]. Management Commentary - The company aims for double-digit pump shipment growth in 2026 and is implementing a pay-as-you-go model in the U.S. to enhance customer access and revenue predictability [4]. - Management is focused on improving margins and profitability to position the company for accelerated sales growth in 2027 and beyond [5]. Market Performance - The stock is currently trading 12.5% above its 20-day simple moving average (SMA) and 15.3% above its 100-day SMA, indicating strong short-term momentum [6]. - Over the past 12 months, shares have increased by 34.4% and are closer to their 52-week highs [6]. Technical Analysis - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure [6][7]. Analyst Consensus - The stock carries a Buy Rating with an average price target of $25.17, and shares were up 37.53% at $25.47 at the time of publication [8]. - Recent analyst actions include upgrades and target raises from various firms, with key resistance at $35 and support at $20 [9].

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reported better-than-expected fourth-quarter financial results on Thursday.Tandem Diabetes Care reported quarterly losses of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $290.400 million which beat the analyst consensus estimate of $277.029 million.Tandem Diabetes Care said it sees FY2026 sales of $1.065 billion to $1.085 billion, versus market estimates of $1.103 billion.“2025 was ...